ClinicalTrials.gg
Not yet recruitingNCT07530653PERMIT-LATAMUpdated May 28, 2026

Delayed Fluids in Hemorrhagic Shock Due to Severe Injuries.

An observational study in Trauma and Emergency Care, Shock,Hemorrhagic and Intravenous Fluid Therapy, sponsored by Hospital Departamental de Villavicencio. Not yet recruiting at 1 site in Colombia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Hospital Departamental de Villavicencio · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
716
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This study will provide information on the quality of care in hemorrhagic shock of severe injuries in a limited resource facility of Latin America, the strategies of fluid resuscitation, and outcomes.

Read the detailed description

Background / Introduction

Trauma remains a leading cause of mortality worldwide, particularly among young and economically productive populations, generating a disproportionate burden in terms of years of life lost, disability, and healthcare expenditures. Hemorrhagic shock is the most common cause of preventable death following trauma, especially within the first hours after injury. Despite advances in trauma systems and critical care, early mortality due to uncontrolled bleeding continues to pose a major clinical challenge.

Traditional resuscitation strategies have emphasized aggressive early fluid administration aimed at restoring normotension. However, growing evidence suggests that this approach may be physiologically detrimental in the setting of uncontrolled hemorrhage. Rapid volume expansion can dislodge forming clots, dilute coagulation factors, exacerbate acidosis, and contribute to the development of trauma-induced coagulopathy. These mechanisms are closely associated with the so-called "lethal triad" of trauma: hypothermia, acidosis, and coagulopathy, which significantly increases mortality risk.

In response to these concerns, the concept of delayed resuscitation, also referred to as permissive hypotension, has emerged as a damage control strategy. This approach aims to limit fluid administration until hemorrhage control is achieved, maintaining a lower-than-normal blood pressure sufficient for minimal organ perfusion while avoiding exacerbation of bleeding. Experimental models and clinical studies have suggested potential benefits, including reduced blood loss, lower transfusion requirements, and improved survival in selected patient populations.

However, the current body of evidence presents important limitations. Many studies have been conducted in high-resource settings with well-developed trauma systems, rapid surgical access, and availability of blood products. Furthermore, heterogeneity in study design, patient populations, injury patterns, and resuscitation protocols limits the generalizability of findings. Importantly, patients with traumatic brain injury, elderly individuals, and those with significant comorbidities may respond differently to hypotensive strategies, raising concerns regarding safety and applicability.

These uncertainties are particularly relevant in low- and middle-income countries (LMICs), including those in Latin America, where the burden of trauma is disproportionately high and healthcare systems often face resource constraints. In such settings, delays in definitive hemorrhage control, limited access to blood products, variability in prehospital care, and constrained intensive care capacity may influence both the feasibility and effectiveness of resuscitation strategies. Consequently, there is a critical need for context-specific evidence to guide clinical decision-making and optimize trauma care protocols in these environments.

Objective

To compare clinical outcomes in patients with hemorrhagic shock due to severe trauma according to the initial fluid resuscitation strategy, specifically delayed (permissive hypotension) versus immediate (conventional) resuscitation, in low-resource healthcare settings in Latin America.

Methods Study Design

This study is designed as a prospective, observational, analytical cohort study conducted in one or more tertiary-level trauma centers in Latin America. The study will adhere to STROBE guidelines for observational research.

Study Population

Eligible participants will include adult patients (≥18 years) presenting with severe trauma and clinical evidence of hemorrhagic shock. Hemorrhagic shock will be defined using a combination of clinical and laboratory criteria, including systolic blood pressure \<90 mmHg, elevated lactate levels, base deficit, and/or clinical signs of hypoperfusion.

Inclusion Criteria Adult patients with major trauma (Injury Severity Score ≥15) Evidence of active bleeding or suspected hemorrhagic shock Admission within a defined time window from injury Exclusion Criteria Severe traumatic brain injury requiring strict blood pressure targets Cardiac arrest prior to hospital arrival Pregnant patients Patients with advanced directives limiting care Exposure Definition

Patients will be categorized based on the initial resuscitation strategy:

Delayed resuscitation group: restricted fluid administration prior to hemorrhage control, targeting permissive hypotension (e.g., systolic blood pressure 80-90 mmHg or presence of radial pulse) Immediate resuscitation group: standard aggressive fluid resuscitation aiming to restore normotension Data Collection

Data will be collected prospectively using standardized case report forms and will include:

Demographic characteristics Mechanism and severity of injury Prehospital and emergency department interventions Hemodynamic parameters and laboratory values Volume of fluids and blood products administered Time to hemorrhage control Outcomes Primary Outcome In-hospital mortality Secondary Outcomes 24-hour mortality Blood product utilization Development of complications (e.g., acute respiratory distress syndrome, multiple organ dysfunction syndrome, acute kidney injury) Length of stay in intensive care unit and hospital Need for surgical or interventional procedures Statistical Analysis

Descriptive statistics will be used to summarize baseline characteristics. Comparisons between groups will be performed using appropriate statistical tests (Chi-square, t-test, or Mann-Whitney U test). Multivariable logistic regression models will be constructed to evaluate the association between resuscitation strategy and outcomes, adjusting for potential confounders such as injury severity, age, mechanism of trauma, and comorbidities.

Propensity score methods may be employed to reduce selection bias and improve comparability between groups. Sensitivity analyses will be conducted to assess robustness of findings.

Expected Results

It is hypothesized that delayed resuscitation will be associated with:

Reduced in-hospital mortality Lower transfusion requirements Decreased incidence of complications related to fluid overload and coagulopathy

However, potential risks, including inadequate organ perfusion and adverse outcomes in specific subgroups, will also be critically evaluated.

02

Conditions studied

  • Trauma and Emergency Care
  • Shock,Hemorrhagic
  • Intravenous Fluid Therapy

Keywords

  • Severe Trauma
  • Hemorrhagic shock
  • Non-compresible torso injuries
  • Delayes resuscitation
  • Permissive hypotension
  • IV fluids
  • Low-resource settings
  • Latin America
  • Trauma systems
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 716 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Hospital Departamental de Villavicencio is the lead sponsor of 16 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hypotensive patients in the emergency department or prehospital care caused by penetrating or blunt injuries.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major injuries.
  • ISS >15.
  • Hypotension with a systolic blood pressure below 90 mmHg.
  • No previous hospital care.
  • Older than 16 years.

Exclusion criteria

Exclusion Criteria:

  • Brain injuries.
  • Pregnancy.
  • Drowning.
  • Burns.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
716 participants (estimated)
Patient registry
No

Groups and cohorts

  • Delayed resuscitation

    IV fluids lower than 1000 mL.

    Drug: Crystalloid below 1000 mL.

  • Immediate resuscitation

    IV fluids \> 1000 mL

    Drug: IV fluids more than 1,000 mL

Interventions

  • DrugCrystalloid below 1000 mL.

    Administration of IV fluids below 1,000 mL on prehospital care.

    Also known as: Restricted IV fluids, Permissive hypotension

  • DrugIV fluids more than 1,000 mL

    Prehospital IV fluids more than 1,000 mL.

    Also known as: High volume resuscitation

06

What researchers measure

Primary outcomes

  1. In-hospital mortality

    Mortality on discharge or before 28 days.

    Time frame: 28 days

Secondary outcomes

  1. Early mortality

    Mortality in the ICU or within 24 hours of admission.

    Time frame: 24 hours.

  2. Coagulopathy

    Bleeding times prolonged \> 1.5 times.

    Time frame: 24 hours.

07

Study locations

1 site
08

References and documents

Publications

  • Deeb AP, Lu L, Guyette FX, Peitzman AB, Daley BJ, Miller RS, Harbrecht BG, Phelan HA, Sperry JL, Brown JB. Optimal Prehospital Crystalloid Resuscitation Volume in Trauma Patients at Risk for Hemorrhagic Shock. J Am Coll Surg. 2023 Aug 1;237(2):183-194. doi: 10.1097/XCS.0000000000000695. Epub 2023 Mar 28. PubMed 36975122 ↗
  • Bernhardt IM, Moore EE, Sauaia A, Cotton BA, Cannon JW, Schreiber MA, Namias N, Minei JP, Wisniewski SR, Guyette FX, Sperry JL; Shock, Whole Blood, and Assessment of Traumatic Brain Injury (SWAT) Study Group. Timing of trauma deaths due to uncontrolled bleeding have not changed in three decades: A multicenter study of patients in hemorrhagic shock. Am J Surg. 2025 Dec;250:116510. doi: 10.1016/j.amjsurg.2025.116510. Epub 2025 Jul 8. PubMed 40706451 ↗
  • Pinsky MR. The Effective Management of Shock: Moving From Physiology to Guidelines to Personalized Medicine. Crit Care Med. 2026 Jun 1;54(6):1495-1502. doi: 10.1097/CCM.0000000000007115. Epub 2026 Mar 17. PubMed 41841954 ↗
  • Penn J, McAleer R, Ziegler C, Cheskes S, Nolan B, von Vopelius-Feldt J. Effectiveness of Prehospital Critical Care Scene Response for Major Trauma: A Systematic Review. Prehosp Emerg Care. 2026;30(2):309-322. doi: 10.1080/10903127.2025.2483978. Epub 2025 Apr 1. PubMed 40131291 ↗
  • Gnanou S, Guertin JR, Tardif PA, Conombo B, Berube M, Yanchar N, Berthelot S, Gnanvi J, Moore L. Cost-effectiveness of specialized trauma care: A systematic review. J Health Serv Res Policy. 2026 Jan;31(1):56-67. doi: 10.1177/13558196251348409. Epub 2025 Jun 4. PubMed 40464624 ↗
  • Bickell WH, Wall MJ Jr, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994 Oct 27;331(17):1105-9. doi: 10.1056/NEJM199410273311701. PubMed 7935634 ↗

Individual participant data

Plan to share: No — Patient's information included.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 15, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Nov 30, 2028
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530653
Lead sponsor
Hospital Departamental de Villavicencio
Responsible party
Norton Perez-Gutierrez, MD (ICU director, Hospital Departamental de Villavicencio) — Principal investigator
First posted
Apr 15, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
May 28, 2026

Study contacts

Norton Perez, MD
Contact
norton.perez@hotmail.com
+573112517471
Emma I Rodriguez Darabos, MSc
Contact
emmaisa1@hotmail.com
3112517538
Norton Perez, MD
principal investigator · Hospital Departamental de Villavicencio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion